1 / 12

Metals in Medicine Consortium Sydney Cancer Centre

Metals in Medicine Consortium Sydney Cancer Centre. Sydney Cancer Centre Clinical Oncology Departments of: Royal Prince Alfred Hospital Medical Oncology Radiation Oncology Surgical Units (urology, melanoma, breast, GI, H&N, cardiothoracic, etc) Palliative Care Haematology

louie
Télécharger la présentation

Metals in Medicine Consortium Sydney Cancer Centre

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Metals in Medicine Consortium Sydney Cancer Centre

  2. Sydney Cancer Centre • Clinical Oncology Departments of: • Royal Prince Alfred Hospital • Medical Oncology • Radiation Oncology • Surgical Units (urology, melanoma, breast, GI, H&N, cardiothoracic, etc) • Palliative Care • Haematology • Concord Hospital • Dubbo Hospital

  3. SCC Clinical Research Links • Pharmaceutical Industry • University of Sydney (Med Psychology, Chemistry, Pharmacology) • Australian cooperative groups (disease specific) • US National Cancer Institute: • US cooperative groups (ph III) • Cornell University phase II consortium (ph II) • CTEP organ dysfunction working group (ph I) • Other international cooperative groups

  4. Essential Clinical Resources for Developmental Therapeutics Research • Clinicians • Patients • Clinical research staff • Regulatory infrastructure • Laboratory interface

  5. SCC Clinical Capability (Medical Oncology) A/Prof Michael Boyer Dr Lisa Horvath Dr Philip Beale Prof John Simes Dr Jane Beith Dr Martin Stockler A/Prof Stephen Clarke Dr Anne Sullivan Dr Anne Hamilton Prof Martin Tattersall • 2000 new patients per year • 200 patients on clinical trials per year • 40 active protocols at any point in time • 12 research staff (nurses / admin) including • RT / Concord / Dubbo

  6. Key SCC Personnel - Metals in Medicine • Dr Philip Beale • Director, Med Oncology, CGRH/Dubbo • GI, gynae, breast, clin pharm • A/Prof Michael Boyer • Director, Med Oncology, CSAHS/RPAH • lung, GU, H&N • A/Prof Stephen Clarke • Head, Clinical Pharmacology • GI, lung, clin pharm • Dr Anne Hamilton • Head, Clinical Trials • breast, melanoma, gynae, clin pharm

  7. End-points of Phase I studies • Recommended phase II dose and schedule • Human toxicology profile • Pharmacokinetics • Pharmacodynamics • Preliminary efficacy data

  8. Role of Clinicians in Developmental Therapeutics Research • Protocol Planning (Registration Strategy) • Patient Selection and Treatment • Translational Laboratory Research Capability (“Bench to Bedside”) • Imaging Capability

  9. Protocol Planning (Registration strategy) • selection of schedule / route of administration • selection of starting dose / dose escalation plan • selection of monitoring according to knowledge of toxicities in drugs of same class / preclinical data • development of strategies for managing side effects / problems as they occur • identification of clinical “niches” for drug development • knowledge of competing molecules

  10. Patient Selection and Treatment • identification of appropriate patients • informed consent • drug administration • monitoring and management of efficacy and toxicity • determination of relationship of clinical events to the study drug • supportive care • reporting (regulatory)

  11. Translational Research Capability“Bench to Bedside” • Concord Laboratory • Cell lines • In vitro drug activity in sensitive and resistant cell lines • Animal (xenografts / immune competent animals) • pharmacokinetics (LCMS) • pharmacodynamics • toxicology • anti-tumour activity

  12. Translational Research Capability“Bench to Bedside” • Human (pretreated cancer / tumour targeted population) • pharmacokinetics (LCMS) • pharmacodynamics • PET labelled compounds (tissue distribution / “real time” PK)

More Related